Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA
R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation
Sylvia Braselmann, Vanessa Taylor, Haoran Zhao, Su Wang, Catherine Sylvain, Muhammad Baluom, Kunbin Qu, Ellen Herlaar, Angela Lau, Chi Young, Brian R. Wong, Scott Lovell, Thomas Sun, Gary Park, Ankush Argade, Stipo Jurcevic, Polly Pine, Rajinder Singh, Elliott B. Grossbard, Donald G. Payan and Esteban S. Masuda
Journal of Pharmacology and Experimental Therapeutics December 2006, 319 (3) 998-1008; DOI: https://doi.org/10.1124/jpet.106.109058
Sylvia Braselmann
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Vanessa Taylor
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Haoran Zhao
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Su Wang
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Catherine Sylvain
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Muhammad Baluom
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Kunbin Qu
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Ellen Herlaar
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Angela Lau
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Chi Young
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Brian R. Wong
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Scott Lovell
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Thomas Sun
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Gary Park
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Ankush Argade
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Stipo Jurcevic
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Polly Pine
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Rajinder Singh
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Elliott B. Grossbard
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Donald G. Payan
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Esteban S. Masuda
Rigel Pharmaceuticals, South San Francisco, California (S.B., V.T., H.Z., S.W., C.S., M.B., K.Q., E.H., A.L., C.Y., B.R.W., T.S., G.P., A.A., P.P., R.S., E.B.G., D.G.P., E.S.M.); deCODE biostructures, Woodridge, Illinois (S.L.); and King's College London, Department of Nephrology and Transplantation, Guy's Hospital, London, United Kingdom (S.J.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA
R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation
Sylvia Braselmann, Vanessa Taylor, Haoran Zhao, Su Wang, Catherine Sylvain, Muhammad Baluom, Kunbin Qu, Ellen Herlaar, Angela Lau, Chi Young, Brian R. Wong, Scott Lovell, Thomas Sun, Gary Park, Ankush Argade, Stipo Jurcevic, Polly Pine, Rajinder Singh, Elliott B. Grossbard, Donald G. Payan and Esteban S. Masuda
Journal of Pharmacology and Experimental Therapeutics December 1, 2006, 319 (3) 998-1008; DOI: https://doi.org/10.1124/jpet.106.109058
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA
R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation
Sylvia Braselmann, Vanessa Taylor, Haoran Zhao, Su Wang, Catherine Sylvain, Muhammad Baluom, Kunbin Qu, Ellen Herlaar, Angela Lau, Chi Young, Brian R. Wong, Scott Lovell, Thomas Sun, Gary Park, Ankush Argade, Stipo Jurcevic, Polly Pine, Rajinder Singh, Elliott B. Grossbard, Donald G. Payan and Esteban S. Masuda
Journal of Pharmacology and Experimental Therapeutics December 1, 2006, 319 (3) 998-1008; DOI: https://doi.org/10.1124/jpet.106.109058
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement